Review article · 2015

Alzheimer’s Disease: Lessons Learned from Amyloidocentric Clinical Trials

Andreas Soejitno, Anastasia Tjan, Thomas Eko Purwata

CNS Drugs, 29(6), 487–502 · Published 1 June 2015 · DOI 10.1007/s40263-015-0257-8

View at the publisherCite this paper

In brief

“Alzheimer’s Disease: Lessons Learned from Amyloidocentric Clinical Trials” is a 2015 review article by Andreas Soejitno and 2 co-authors, published in CNS Drugs. OpenAlex counts 35 citations as of 20 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
35
Most cited in
2017 (9)
Field-weighted impact
0.59
References
126
Authors
3

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Soejitno, A., Tjan, A., & Purwata, T. E. (2015). Alzheimer’s Disease: Lessons Learned from Amyloidocentric Clinical Trials. CNS Drugs, 29(6), 487–502. https://doi.org/10.1007/s40263-015-0257-8

MLA 9

Soejitno, Andreas, et al. “Alzheimer’s Disease: Lessons Learned from Amyloidocentric Clinical Trials.” CNS Drugs, vol. 29, no. 6, 2015, pp. 487–502. https://doi.org/10.1007/s40263-015-0257-8.

Chicago

Soejitno, Andreas, Anastasia Tjan, and Thomas Eko Purwata. 2015. “Alzheimer’s Disease: Lessons Learned from Amyloidocentric Clinical Trials.” CNS Drugs 29 (6): 487–502. https://doi.org/10.1007/s40263-015-0257-8.

Harvard

Soejitno, A., Tjan, A. and Purwata, T. E. (2015) ‘Alzheimer’s Disease: Lessons Learned from Amyloidocentric Clinical Trials’, CNS Drugs, 29(6), pp. 487–502. doi:10.1007/s40263-015-0257-8.

IEEE

A. Soejitno, A. Tjan, and T. E. Purwata, “Alzheimer’s Disease: Lessons Learned from Amyloidocentric Clinical Trials,” CNS Drugs, vol. 29, no. 6, pp. 487–502, 2015, doi: 10.1007/s40263-015-0257-8.

BibTeX

@article{soejitno2015alzheimer,
  title     = {{Alzheimer’s Disease: Lessons Learned from Amyloidocentric Clinical Trials}},
  author    = {Soejitno, Andreas and Tjan, Anastasia and Purwata, Thomas Eko},
  journal   = {CNS Drugs},
  year      = {2015},
  volume    = {29},
  number    = {6},
  pages     = {487--502},
  doi       = {10.1007/s40263-015-0257-8},
  url       = {https://doi.org/10.1007/s40263-015-0257-8}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201655
201799
201855
202055
202133
202211
202322
202422
202622

Its field-weighted citation impact is 0.59: it has been cited 0.59 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments

  • Alzheimer's disease
  • amyloid hypothesis
  • amyloid-beta
  • tau protein
  • disease-modifying therapy
  • prophylaxis
  • diagnostic criteria

Work with this paper

Most-cited papers in Neuroscience

All highly cited Neuroscience papers

Questions about this paper

How do I cite this paper in APA style?

Soejitno, A., Tjan, A., & Purwata, T. E. (2015). Alzheimer’s Disease: Lessons Learned from Amyloidocentric Clinical Trials. CNS Drugs, 29(6), 487–502. https://doi.org/10.1007/s40263-015-0257-8

How many times has this paper been cited?

35 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Andreas Soejitno, Anastasia Tjan, Thomas Eko Purwata.

What is the DOI of this paper?

10.1007/s40263-015-0257-8, permanently at https://doi.org/10.1007/s40263-015-0257-8. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.